Results 171 to 180 of about 78,942 (265)

Gout and comorbidity: a nominal group study of people with gout [PDF]

, 2017
Jasvinder A. Singh
openalex   +1 more source

Clinical obesity and Himan‐sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesity care

Journal of Diabetes Investigation, EarlyView.
Wataru Ogawa, Iichiro Shimomura, Toshimasa Yamauchi, Koutaro Yokote   +3 more
wiley   +1 more source

Safety and Tolerability of Withania somnifera Root Extract in Healthy Male Participants: A Pilot Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Food Science &Nutrition, Volume 14, Issue 1, January 2026.
Withania somnifera (WS) or Ashwagandha is valued for its anti‐inflammatory, antioxidant, adaptogenic, and memory‐enhancing properties. This randomized, placebo‐controlled and double‐blind study assessed the safety of standardized WS root extract in healthy adult participants over 180 days. The study concluded that WS root extract (200 mg capsules twice
Narendra Vaidya, Ramshyam Agarwal, Pankaj Kshirsagar, Gayatri Ganu, Dheeraj Nagore, Anirudh Mehta, Ashit Vora, Sujit Nair   +7 more
wiley   +1 more source

UK Biobank: Transforming drug discovery and precision medicine

British Journal of Pharmacology, Volume 183, Issue 2, Page 234-248, January 2026.
UK Biobank is a large‐scale, prospective study with extensive genetic and phenotypic data on half a million individuals. Volunteers, aged between 40 and 69 years, were recruited between 2006 and 2010 from the general population of the United Kingdom.
Jelena Bešević, Saredo Said, Reka Nagy, Yalda Jamshidi, Christopher D. Whelan, Lauren Carson, Martin K. Rutter, Adam J. Lewandowski, Mark Effingham, Rory Collins, Ben Lacey, Naomi E. Allen   +11 more
wiley   +1 more source

Global burden of gout in age groups 10 to 54 years from 1990 to 2021: Trend of the global burden of disease study. [PDF]

Medicine (Baltimore)
Shi K, Guo Y, You T.
europepmc   +1 more source

The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout [PDF]

, 2016
Alexandra Steinberg, Bradley Vince, Yun‐Jung Choi, Robert L. Martin, Charles A. McWherter, Pol Boudes   +5 more
openalex   +1 more source

Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 186-196, January 2026.
Abstract Aims To evaluate medication adherence in patients with type 2 diabetes (T2D) using plasma drug measurements and assess the clinical impact of partial non‐adherence on glycemic control and complications. Materials and Methods This cross‐sectional study included 641 T2D outpatients attending routine follow‐up visits.
Vojtěch Škop, Ivana Laňková, Simona Antalová, Iva Míšková, Kateřina Malá‐Ládová, Josef Malý, Terezie Pelikánová, Jiří Hricko, Tomáš Čajka, Martin Haluzík   +9 more
wiley   +1 more source

Lobeglitazone improves glycaemic control as add‐on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double‐blind, randomised, placebo‐controlled trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 728-740, January 2026.
Abstract Aims This study aimed to evaluate the efficacy and safety of triple therapy with lobeglitazone 0.5 mg as an add‐on treatment compared with placebo in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.
Da Hea Seo, Kyung Wan Min, Ho Sang Sohn, Sang Yong Kim, In‐Kyung Jeong, Cheol‐Young Park, Kun‐Ho Yoon, So Hun Kim, Bong‐Soo Cha   +8 more
wiley   +1 more source

Risk factors for early-onset hyperuricemia and gout following laparoscopic sleeve gastrectomy: a retrospective study. [PDF]

BMC Surg
Fu C, Han Y, Chen J, Chen J, Chen Y, Liang X, Sun L.   +6 more
europepmc   +1 more source

Importance and Potential of Rare Disease Research in Pediatric Rheumatology and Beyond: Pushing Frontiers

ACR Open Rheumatology, Volume 7, Issue 12, December 2025.
Although individually occurring in less than 1 in 2,000 people, cumulatively, more than 7,000 rare diseases affect approximately 6% of the population worldwide. Children and young people are disproportionally challenged in number and severity, which may be explained by the large proportion of genetic conditions among rare diseases (70%–80%). Indeed, an
Christian M. Hedrich
wiley   +1 more source